Alexander Zverev's Grand Slam win highlights challenges of Type 1 diabetes in professional sports
Alexander Zverev's recent French Open victory, making him the first Type 1 diabetes (T1D) patient to win a Grand Slam, has brought significant attention to managing this chronic condition in elite sports. Diagnosed at age four, Zverev relies on insulin therapy and continuous glucose monitoring (CGM) to manage fluctuating blood sugar levels, a process he describes as 'playing two games at once.' The article explains T1D, the risks of hyperglycaemia and hypoglycaemia, and the physical and mental burdens faced by athletes, including issues like 'Ozempic face,' hair shedding, and the need for careful nutritional and aesthetic planning. Zverev also advocates for TID awareness through his foundation.
Key Points
- Alexander Zverev's French Open win marks a historic achievement for an athlete with Type 1 diabetes (T1D).
- Managing T1D in elite sports involves constant monitoring of blood glucose levels and insulin administration.
- Athletes face challenges like hyperglycaemia, hypoglycaemia, and physical/mental burnout due to the condition.
- GLP-1 based medicines, while not beauty drugs, can have visible dermatological consequences like facial volume loss and hair shedding.
- Zverev advocates for T1D awareness and has established a foundation to support children with diabetes.
Exam Facts
- Athlete: Alexander Zverev, Germany.
- Grand Slam win: 2026 French Open.
- Condition: Type 1 Diabetes (T1D), diagnosed at age four.
- Tools for management: Insulin pens, continuous glucose monitoring (CGM).
- A 2025 study by University of Georgia found hypervigilance for T1D causes burnout.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.